Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

6.25HKD
9:28am IST
Change (% chg)

HK$-0.01 (-0.16%)
Prev Close
HK$6.26
Open
HK$6.30
Day's High
HK$6.33
Day's Low
HK$6.21
Volume
3,991,500
Avg. Vol
11,689,287
52-wk High
HK$7.90
52-wk Low
HK$4.88

Latest Key Developments (Source: Significant Developments)

Luye Pharma Group Says Ly01008 (Biosimilar To Avastin) Completed Primary Endpoint Observation
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP LTD - LY01008 (BIOSIMILAR TO AVASTIN) COMPLETED PRIMARY ENDPOINT OBSERVATION FOR PHASE III CLINIC TRIAL IN CHINA.  Full Article

Luye Pharma Group Says Received Establishment Inspection Report From U.S. FDA
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Luye Pharma Group Ltd <2186.HK>::RECEIVED ESTABLISHMENT INSPECTION REPORT FROM U.S. FOOD AND DRUG ADMINISTRATION.REPORT INDICATES MANUFACTURING FACILITY IN YANTAI, CHINA PASSED PRE-APPROVAL INSPECTION WITH NO FDA-483, INSPECTION OBSERVATION.  Full Article

Luye Pharma Says NMPA Approves Xuezhikang Tablets (LY02404) To Initiate Clinical Trials In China
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Luye Pharma Group Ltd <2186.HK>::XUEZHIKANG TABLETS (LY02404) HAS BEEN APPROVED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) TO INITIATE CLINICAL TRIALS IN CHINA.  Full Article

Luye Pharma Group Announces Adjustment To Conversion Price Of U.S.$300 Mln Convertible Bonds Due 2024
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP ANNOUNCES ADJUSTMENT TO CONVERSION PRICE OF U.S.$300 MILLION 1.50 PER CENT. CONVERTIBLE BONDS DUE 2024.CONVERSION PRICE OF BONDS WILL BE ADJUSTED FROM HK$8.15 PER SHARE TO HK$8.05 PER SHARE WITH EFFECT FROM 14 SEPT.  Full Article

Luye Pharma Group Says HY Net Profit Increased By 36.9% To RMB770.8 BLN
Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - Luye Pharma Group Ltd <2186.HK>::HY NET PROFIT INCREASED BY 36.9% TO RMB770.8 MILLION.HY REVENUE INCREASED BY 42.1% TO RMB3,130.9 MILLION.DECLARED AN INTERIM DIVIDEND OF RMB0.059 PER SHARE FOR SIX MONTHS ENDED 30 JUNE 2019.  Full Article

Luye Pharma Group Says Co Submitted Clinical Trial Application For Tablets In Japan
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Luye Pharma Group Ltd <2186.HK>::SUBMITTED CLINICAL TRIAL APPLICATION FOR ANSOFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS IN JAPAN.  Full Article

Luye Pharma Group Announces Proposed Issue Of US$300 mln 1.50 Pct. Convertible Bonds Due 2024
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Luye Pharma Group Ltd <2186.HK>::PROPOSED ISSUE OF US$300 MILLION 1.50 PER CENT. CONVERTIBLE BONDS DUE 2024.  Full Article

Pharma Mar And Luye Pharma Sign Deal For Development And Sale Of Lurbinectedin In China Territories
Friday, 26 Apr 2019 

April 26 (Reuters) - Pharma Mar SA ::PHARMAMAR AND LUYE PHARMA <<<2186.HK>>> SIGN LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF LURBINECTEDIN IN CHINA TERRITORIES.TO RECEIVE UP-FRONT PAYMENT OF $5 MILLION .OTHER PAYMENTS WILL FOLLOW FOR REGULATORY MILESTONES AND, IN ADDITION, FOR SALES AND ROYALTIES.LUYE PHARMA TO DEVELOP LURBINECTEDIN IN SCLC IN CHINA, WHILE PHARMAMAR TO RETAIN EXCLUSIVE PRODUCTION RIGHTS FOR THE COMPOUND.  Full Article

Luye Pharma Group Posts FY Profit Attributable Rmb1,303.4 Mln
Thursday, 28 Mar 2019 

March 28 (Reuters) - Luye Pharma Group Ltd <2186.HK>::FY REVENUE RMB5,173.4 MILLION, UP 35.6 PERCENT.FY PROFIT ATTRIBUTABLE RMB1,303.4 MILLION, UP 32.8 PERCENT.BOARD PROPOSES A FINAL DIVIDEND OF RMB0.057 PER SHARE.  Full Article

Luye Pharma says Innovative Drug Risperidone Extended Release Microspheres For Injection Reaches Final Stage Of NDA Process
Monday, 31 Dec 2018 

Dec 30 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP ANNOUNCES INNOVATIVE DRUG RISPERIDONE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS REACHED FINAL STAGE OF NDA PROCESS.SUCCESSFULLY REACHED AN AGREEMENT WITH FDA TO WAIVE ALL PAEDIATRIC CLINICAL STUDIES OF LY03004.OBTAINED FDA'S APPROVAL OF USING RYKINDO AS LY03004'S BRAND NAME FOR TREATMENT OF SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER.  Full Article